Table 1.
Inhibition of iPFK-2 expression decreases human tumor cell proliferation in vitro
| Cell line | iPFK-2 AS | Percent inhibition | mean ± SD |
|---|---|---|---|
| HL60 | A | 32.0 ± 15.0 | P = 0.029 |
| B | 48.0 ± 22.0 | P = 0.006 | |
| MOLT4 | A | 32.6 ± 7.5 | P = 0.00004 |
| B | 49.5 ± 6.1 | P = 0.00002 | |
| SW480 | A | 28.7 ± 19.3 | P = 0.009 |
| B | 37.7 ± 12.6 | P = 0.0005 | |
| KG1a | A | 51.5 ± 19.5 | P = 0.022 |
| B | 58.6 ± 25 | P = 0.001 | |
| G361 | A | 19.6 ± 9.4 | P = 0.001 |
| B | 24.4 ± 11.1 | P = 0.002 |
Cells were cultured and transfected with two different iPFK-2 antisense oligonucleotides (AS: A or B). The G361 is a melanoma cell line. Proliferation was measured by the incorporation of [3H]thymidine (4 μCi/ml) (DuPont) into DNA over the last 16 hr of incubation. Percent inhibition was calculated relative to the corresponding sense control, which did not show any effect on baseline proliferation. All data are expressed as the mean ± SD of three experiments. Statistical significance was assessed by the two-sample t test (independent variable).